Dr. Guha is a physician scientist with more than 15 years of clinical development experience across academia, pharma, and biotech, with expertise in targeted therapy, immunotherapy, and cellular therapy. He currently serves as Chief Medical Officer at NextCure. Previously, he was VP, Head of Clinical Development at TCR2 Therapeutics, now part of Adaptimmune, and led several first-in-class, first-in-human immunotherapy studies at Bristol Myers Squibb. Earlier, he was an Investigator at the NCI/NIH, where he led lung cancer research focused on tumor heterogeneity and resistance to EGFR TKIs. He earned his MBBS from AIIMS in New Delhi, a Ph.D. in Neuroscience from Albert Einstein College of Medicine, completed residency at Jacobi Medical Center, and fellowship at MSKCC, including postdoctoral research with Nobel Laureate Dr. Harold Varmus.